- COMMENT
Personalized profiles for disease risk must capture all facets of health
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 597, 175-177 (2021)
doi: https://doi.org/10.1038/d41586-021-02401-0
Disclaimer: M.M.’s views in this article are his own and not those of Genentech.
References
Torkamani, A., Wineinger, N. E. & Topol, E. J. Nature Rev. Genet. 19, 581–590 (2018).
Lambert, S. A., Abraham, G. & Inouye, M. Hum. Mol. Genet. 28, R133–R142 (2019).
Sud, A., Turnbull, C. & Houlston, R. NPJ Precis. Oncol. 5, 40 (2021).
Erdmann, J., Kessler, T., Munoz Venegas, L. & Schunkert, H. Cardiovasc. Res. 114, 1241–1257 (2018).
Khera, A. V. et al. Nature Genet. 50, 1219–1224 (2018).
Mavaddat, N. et al. Am. J. Hum. Genet. 104, 21–34 (2019).
Martin, A. R. et al. Nature Genet. 51, 584–591 (2019).
Fahed, A. C. et al. Nature Commun. 11, 3635 (2020).
Mars, N. et al. Nature Commun. 11, 6383 (2020).
Mostafavi, H. et al. eLife 9, e48376 (2020).
Competing Interests
M.M. is an employee of Genentech and holds stocks and shares in Roche. E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to Dovetail, and a non-executive director of Genomics England, a limited company wholly owned by the UK Department of Health and Social Care.